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Abstract: Patients with multiple myeloma (MM) treated with conventional chemotherapy have an average
survival of approximately three years. High dose chemotherapy followed by autologous stem cell transplanta-
tion (ASCT), first introduced in the mid-1980s, is now considered the standard therapy for almost all patients
with multiple myeloma, because it prolongs overall survival and disease free survival. Between November 1997
and October 2006, 122 patients with MM (58 females, 64 males, median age 51.0 years [± 7.98] range: 30–66
years) were transplanted in the Department of Hematooncology and Bone Marrow Transplantation at the Med-
ical University of Lublin: 47 patients were in complete remission or in unconfirmed complete remission,
66 patients were in partial remission, and nine had stable disease. Of these, there were 95 patients with IgG myelo-
ma, 16 with IgA myeloma, one with IgG/IgA, one with IgM myeloma, five with non secretory type, two with
solitary tumor and two with LCD myeloma. According to Durie-Salmon, 62 patients had stage III of the disease,
46 had stage II and four had stage I. Most patients (69/122) were transplanted after two or more cycles of
chemotherapy, 48 patients were transplanted after one cycle of chemotherapy, one patient after surgery and rtg-
-therapy and four patients had not been treated. In mobilisation procedure, the patients received a single infu-
sion of cyclophosphamide (4–6 g/m2) or etoposide 1.6 g/m2 followed by daily administration of G-CSF until the
peripheral stem cells harvest. The number of median harvest sessions was 2.0 (± 0.89) (range: 1–5). An average
of 7.09 (± 33.28) × 106 CD34+ cells/kg were collected from each patient (range: 1.8–111.0 × 106/kg). Condition-
ing regimen consisted of high dose melphalan 60–210 mg/m2 without TBI. An average of 3.04 (± 11.59) × 106
CD34+ cells/kg were transplanted to each patient. Fatal complications occured in four patients (treatment-
-related mortality = 3.2%). In all patients there was regeneration of hematopoiesis. The median number of days
for recovery to ANC > 0.5 × 109/l was 13 (± 4.69) (range: 10–38) and platelets recovery to > 50 × 109/l was 25
days (± 11.65) (range: 12–45). Median time of hospitalization was 22 days (± 7.14) (range: 14–50). Patients
were evaluated on day 100 after transplantation: 74.9% achieved CR and nCR, 14.3% were in PR, 5.4% had SD
and 5.4% had progressed. Median of OS was 45 months (± 30.67). OS at 3-years was 84% and at 7-years 59%.
Median PFS was 25 months (± 26.13). PFS at 3-years was 68%, and at 7-years was 43%. At present (November
2009) 52 patients (42%) are still alive. High-dose chemotherapy followed by autologous stem cell transplanta-
tion is a valuable, well tolerated method of treatment for patients with MM that allows the achievement of long-
-lasting survival. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 248–254)
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Introduction
Patients with multiple myeloma (MM) treated with
conventional chemotherapy have an average survival
of approximately three years. After induction thera-
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py with ‘old’ drugs complete remission (CR) was
achieved only in 3–13% of MM patients [1]. Be-
cause of the obvious resistance to conventional
chemotherapy in MM, high-dose chemotherapy
with autologous stem cell transplantation (ASCT)
has become during the last decade the gold stan-
dard for patients aged below 65. A randomized
trial by the Intergroupe Francais du Myelome
(IFM) first showed a better outcome with high-
-dose therapy than with standard chemotherapy in
200 patients with newly diagnosed disease, with
a response rate (RR) increased to 50% and overall
survival (OS) > 5 years [2]. Novel agents such as
thalidomide (Talizer), bortezomib (Velcade) and
lenalidomide (Revlimid) have been introduced to
improve results of initial therapy before ASCT or
as rescue regimens for refractory/relapsed disease.
Using these drugs in combination with cyclophos-
phamide, dexamethasone and antracyclins has
achieved RR up to 95% and CR rate up to 44%
before ASCT [3, 4].
The results of myeloablative allogeneic transplan-
tation still remain disappointing due to high trans-
plantation-related mortality. Therefore it not recom-
mended as a routine procedure even for younger pa-
tients with MM.
Material and methods
Patients and disease characteristics. Between November
1997 and December 2006, 122 patients with MM were trans-
planted in the Department of Hematooncology and Bone
Marrow Transplantation in the Medical University of Lub-
lin. Clinical charactersictics of the patients are presented in
Table 1.
ASCT procedure. Peripheral blood stem cells (PBSC)
collection. After induction therapy, all patients received
a single infusion of cyclophosphamide (4–6 g/m2) or an infu-
sion of etoposide (1.6 g/m2 divided into two doses) followed
by daily i.v. administration of G-CSF at a dose of 10 ug/kg
from day +5 or from +3 for the etoposide regimen until
the peripheral stem cell harvest. Peripheral blood stem cells
(PBSC) were collected during an average of two aphereses
(± 0.89), (range: 1–5) on Haemonetics or a Baxter cell sep-
arator. The median number of collected CD34+ cells was
7.09 × 106/kg (± 33.28) (range: 1.8–111.0 × 106) per pa-
tient. Transplant material was stored at 10% DMSO and
autologous plasma or 5% albumins in –180°C, without rate
controlled freezing.
Transplantation procedure. High-dose therapy consisted
of melphalan (MEL) given i.v. at a dose of 200 mg/m2 or
140 mg/m2, followed by infusion of a median 3.04 × 106/kg
(± 11.59), (range: 1.15–5.0 × 106/kg) non selected CD34+
cells on day 0. TBI was not used. G-CSF was administered
subsequently i.v. at a dose of 5–10 ug/kg.
In 25 patients, tandem transplants were performed.
They received MEL 200 mg/m2 or 140 mg/m2 and one of
them received Busulfan 4 mg/kg followed by reinfusion of
stem cells.
Results
Patients were evaluated on day 100 after transplanta-
tion. 74.9% achieved CR and nCR, 14.3% were in
PR, 5.4% of them had SD and 5.4% progressed.
Median OS was 45 months (± 30.67) for patients
with one transplantation, and 83 months (± 32.35)
for doubly transplanted patients, p = 0.1089. Progres-
sion free survival (PFS) was median 25 months
Table 1. Clinical characteristics of transplanted patients
Total number of transplanted patients 122
Number of patients with double transplantation 25
Age (years, median) 51.0 (± 7.98)
(range: 30–66)
Female/male (number) 59/63
Disease characteristics (number of patients)
IgG MM 94
IgA MM 17
IgG/IgA MM 1
IgM MM 1
Light chain disease 2
Non secretory MM 5
Plasmacytoma 2
Kappa chain MM 98
Lambda chain MM 21
No data 3
Stage I (acc. Durie-Salmon) 4
Stage II (acc. Durie-Salmon) 46
Stage III (acc. Durie-Salmon) 62
No data 8
Therapy before transplantation
(number of patients)
One cycle of chemotherapy
(VAD or VMBCP or THAL)*
Two or more cycles of chemotherapy
(VAD, EDAP, CTD, VD,THAL, MP)*
Surgery and rtg therapy 8
Any treatment 4
Status before transplantation (number of patients)
nCR 3
CR 44
PR 66
SD 5
Not treated 4
* VAD — vincristine, adriblastine, dexamethasone;
VMBCP — vincristine, melphalan, carmustine, cyclophosphamide,
prednisone; THAL — thalidomide; EDAP — etoposide, dexamethasone,
arabinoside cytosine, cisplatine; CTD — cyclophosphamide, thalidomide,
dexamethasone, MP — melphalan, prednisone; VD — vinorelbine,
dexamethasone
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(± 26.13) in the first group and 45 months (± 30.73)
in the second group, p = 0.1043.
In all patients, OS at 3-years was 84%, PFS was
68%; at 7-years, OS was 59% and PFS was 43% (Fig-
ures 1–3). At present (November  2009) 52 patients
(42%) are still alive.
The clinical course of transplantation is summa-
rized in Table 2, and the results of ASCT are shown
in Table 3.
Discussion
MM is characterized by a marked resistance to con-
ventional chemotherapy. It has been shown that drug
resistance can be overcome by dose escalation [5–7].
High-dose therapy with MEL was introduced in the
mid-1980s [8]. The IFM randomized trial first dem-
onstrated the superiority of high-dose therapy sup-
ported by autologous bone marrow transplantation
compared to conventional chemotherapy, with OS at
7-years of 43% vs. 27% (p < 0.03) and EFS at 7-years
of 16% vs. 8% (p < 0.01) [2]. Five more trials were
performed to compare ASCT versus conventional
chemotherapy, and whereas three of them showed no
benefit in terms of EFS or OS [9–11],  the other two
confirmed the benefit, with median OS of 54 months
and OS at 3-years of 77% [12, 13].
Many factors can be responsible for ASCT out-
come, including biological and individual factors be-
fore transplantation, genetic factors, biological pa-
rameters, b2-microglobulin and albumin levels form-
ing International Staging System, sensitivity to ini-
tial chemotherapy, and proliferative index [14, 15].
CR status before ASCT has been revealed to be the
most important factor contributing to a long-lasting
response and prolonged survival in patients with MM
[16, 17]. Sensitivity to initial chemotherapy measured
by the M-protein type at time of transplant is the
most reliable predictor of CR after ASCT [16, 17].
A recent meta-analysis carried out by Van de Velde
et al. also confirmed the strong association between
maximal response to induction therapy and long-
term outcome after ASCT [18]. The chromosomal
abnormalities del(13), t(4,14) and del(17p) have
been associated with a shorter survival after ASCT
and have become a marked risk factor for all MM
patients [19].
Novel agents (i.e. thalidomide, lenalidomide and
bortezomib) have been introduced. They have an in-
creased anti-myeloma effect and prolong survival due
to better results of initial therapy before ASCT and/
/or more effective rescue regimens for patients with
relapsed/refractory disease.
Thalidomide-based regimens as initial therapy in
multiple myeloma: TD (thalidomide + dexametha-
sone); TAD (thalidomide + dexamethasone + adri-
amycin); and CTD (cyclo-phosphamide + thalido-
mide + dexamethasone) have resulted in raising the
response rate (RR) –72% to 87% and CR rate up to
19% before ASCT. After transplantation, RR rate
increased to 88%, including CR and nCR rates up to
51% [20, 21].
Lenalidomide-based therapy was applied in MM
patients in two trials conducted by ECOG and SWOG
with RR 82% and 85% respectively and CR rate 4%
and 22% before transplantation, with OS at 4-years
92% after ASCT [22].
Bortezomib in combination with thalidomide or
lenalidomide or anthracyclins or dexamethasone
boosted RR from 60% to 95%, with 10% to 44% CRs.
In all these pilot studies, the CR markedly increased
after transplantation (31–57%) [3, 4].
During the nine years of this study, 122 patients
with multiple myeloma were transplanted in the De-
partment of Hematooncology and Bone Marrow
Transplantation in Lublin. Different regimens before
ASCT were applied: VAD, EDAP, VMBCP, CTD,
Table 2. Clinical data during transplantation
 Duration of neutropenia (median, days) 13
(range: 10–38)
Duration of thrombocytopenia (median, days) 25
(range: 12–45)
Days of hospitalization (median) 22
(range: 14–50)
Days of G-SCF administration (median) 14
(range: 0–33)
Transplant-related toxicity
Transplant-related mortality 4 (3.2%)
(number of patients, %)
Mucositis grade gr. 3/4 WHO 24/122
(number of patients)
Sepsis (number of patients) 2/122
Pneumonia (number of patients) 1/122
Infections of CVC (number of patients) 20/122
Cardiac toxicity (MAS, FA) 2/122
(number of patients)
Table 3. Comparison of clinical status before and after ASCT
Status before Status at day +100
transplantation (%)  after ASCT (%)
nCR 3.3 2.7
CR 35.8 72.2
PR 53.6 14.3
SD 7.3 5.4
Relapse 5.4
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Median Mean SD
APSCT 66.41 74.83 36.49
Chemotherapy 27.00 33.14 22.89
Figure 1. Overall survival of transplanted patients in contrast to conventional chemotherapy in Department of Hemato-
oncology and Bone Marrow in Lublin data (months)
Median Mean SD
  1 × APSCT 45.07 54.79 30.67
  2 × APSCT 83.05 75.57 32.35
Figure 2. Overall survival of transplanted patients (months) — 122 pts
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thalidomide alone, and vinorelbine with dexam-
ethasone. We tried to obtain the best response be-
fore transplantation. Only a few patients received
one cycle; most received two or more cycles of ther-
apy. RR was high: 92.7% with CR and nCR rate
was 39.1%. After ASCT, 74.9% of patients obtained
CR and nCR, 14.3% PR, 5.4% of them had SD and
5.4% had progressed. Median of OS was 45 months,
OS at 3-years was 85% and at 7-years was 59%.
TRM was low at 3.2%. Published data referring to
TRM at that time gave figures ranging from 2.7%
to 10% [23, 24].
Autologous stem cell transplantation does not
cure the condition. Most patients will relapse with-
in a median of three years. It has been suggested
that double transplantation could be more effec-
tive than single transplantation to cure patients with
multiple myeloma or to prevent relapse. The IFM
94 study compared single versus double ASCT
among 399 patients and showed no benefit of dou-
ble ASCT: at 7-years OS was 21% and EFS 20%.
This trial confirmed the benefit of double ASCT
only in patients who failed to achieve a very good
partial response after the first transplantation [25].
Four further trials comparing single versus double
transplantation were conducted, and two of them
reported a survival benefit in favour of tandem
transplantation [10, 26–28].
In 25 patients, tandem transplantation was per-
formed in our centre. OS was median 83 months
(± 32.35), mean 75.57 months and PFS was 45 months
(± 30.73), mean 47.38 months. They reached OS at
7-years 73%, compared to OS 59% in once transplant-
ed patients and EFS 67% vs. 43% respectively. But
in longer observation (ten years) there were no sig-
nificant differences observed in OS and EFS when
comparing single versus double transplantation.
Maintenance therapy after ASCT has been applied
for many years in MM patients. First, interferon al-
pha prolonged PFS and OS by between 4 and 8
months [29]. The IFM group and the Australian group
showed that maintenance therapy with thalidomide
prolonged duration of PFS and OS after ASCT
[30, 31]. In the IFM trial, OS at 4-years was 87% and
PFS at 3-years was 52%. In the Australian group, OS
at 3-years was 86% and PFS at 3-years was 42%. To-
day, thalidomide is recommended as a maintenance
therapy for less than 12 months and for patients who
do not achieve CR after ASCT. Lenalidomide is now
considered as the ideal maintenance drug, but clini-
cal trials are still ongoing. We used routine mainte-
nance therapy with thalidomide at a dose of 100 mg
daily or interferon alpha at a dose of 3 mln U/three
times weekly in cases where CR or nCR after ASCT
was not obtained. These therapies were applied until
progression and were well tolerated.
Median Mean SD
  1  × APSCT 25.02 34.12 26.13
  2  × APSCT 45.38 47.38 30.73
Figure 3. Progression free survival after transplantation (months) — 122 pts
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ASCT is currently considered to be the standard
therapy for younger patients with MM, safe due to
a low mortality rate (1–2%), with benefits in terms of
response rate, particulary in EFS with ranges between
25 and 42 months compared to conventional chemo-
therapy. Patients after ASCT have a very good quali-
ty of life, with some of them requiring only mainte-
nance therapy instead of sequential chemotherapy.
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